Followers | 2541 |
Posts | 250759 |
Boards Moderated | 35 |
Alias Born | 05/06/2014 |
![](https://investorshub.advfn.com/uicon/477208.png?cb=1464790659)
Saturday, July 07, 2018 5:51:05 PM
2018 EPS Estimate: $0.41
2019 EPS Estimate: $2.44 (+495.1%)
Stock Price: $70.83
P/E Ratio: 110.7
Consensus Rating: Buy
Ratings Breakdown: 15 Buy Ratings, 7 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $107.7839 (52.2% Upside)
Recent INCY News
- Incyte präsentiert bahnbrechende Phase 3-Ergebnisse für Retifanlimab (Zynyz®) und erste Daten aus Phase 1 des CDK2-Inhibitor-Programms auf dem Kongress der European Society of Medical Oncology (ESMO) 2024 • Business Wire • 08/21/2024 08:49:00 PM
- Incyte présentera les résultats de la phase 3 de Retifanlimab (Zynyz®) et les données initiales du programme d'inhibiteurs de CDK2 de phase 1 à l'édition 2024 du Congrès de la Société européenne d'oncologie médicale (ESMO) • Business Wire • 08/21/2024 08:49:00 PM
- Incyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz®) and Initial Data from Phase 1 CDK2 Inhibitor Program at the European Society of Medical Oncology (ESMO) Congress 2024 • Business Wire • 08/21/2024 03:40:00 PM
- Incyte gibt positive Topline-Ergebnisse der Pivotalstudie mit Tafasitamab (Monjuvi®) bei rezidiviertem oder refraktärem follikulärem Lymphom bekannt • Business Wire • 08/16/2024 09:59:00 AM
- Incyte annonce des résultats positifs de l'étude pivot sur le tafasitamab (Monjuvi®) dans le lymphome folliculaire récidivant ou réfractaire • Business Wire • 08/16/2024 09:46:00 AM
- Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma • Business Wire • 08/15/2024 08:30:00 PM
- Incyte und Syndax melden FDA-Zulassung von Niktimvo™ (Axatilimab-csfr) zur Behandlung der chronischen Graft-versus-Host-Krankheit (GvHD) • Business Wire • 08/15/2024 08:15:00 PM
- Incyte et Syndax annoncent l’approbation par la FDA américaine de Niktimvo™ (axatilimab-csfr) pour le traitement de la maladie chronique du greffon contre l’hôte (GVHD) • Business Wire • 08/15/2024 10:26:00 AM
- Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD) • Business Wire • 08/14/2024 09:34:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 07:37:17 PM
- Incyte to Present at Upcoming Investor Conferences • Business Wire • 08/13/2024 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/12/2024 08:39:53 PM
- Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 08/07/2024 09:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 11:15:24 AM
- Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs • Business Wire • 07/30/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/29/2024 07:50:27 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/25/2024 08:09:28 PM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 07/24/2024 06:20:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 04:31:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 04:30:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 04:29:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 04:29:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 04:28:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 04:28:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 04:27:28 PM
Element79 Gold Corp Appoints Warren Levy to Board of Directors • ELMGF • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM